Crossmark

Re-evaluating the survival benefit of adding camrelizumab to TACE plus tyrosine-kinase inhibitors in unresectable hepatocellular carcinoma: the undervalued influence of TACE frequency

Crossref DOI link: https://doi.org/10.1016/j.aohep.2025.102126

Published Print: 2025-07

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Wang, Longshuang

Zhang, Jian

Liu, Jianfei
License Information

Text and Data Mining valid from 2025-07-01

Text and Data Mining valid from 2025-07-01

Version of Record valid from 2025-09-23
More Information

This article is maintained by: Elsevier

Article Title: Re-evaluating the survival benefit of adding camrelizumab to TACE plus tyrosine-kinase inhibitors in unresectable hepatocellular carcinoma: the undervalued influence of TACE frequency

Journal Title: Annals of Hepatology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.aohep.2025.102126

Content Type: simple-article

Copyright: © 2025 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U.

Document is current

Any future updates will be listed below